HLA class I downregulation is associated with enhanced NK‐cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors

The frequent development of drug resistance to targeted therapies in cancer patients has stimulated interest in strategies counteracting resistance. Combining immunotherapies with targeted therapies is one such strategy. In this context, we asked whether human NK cells can target melanoma cells that...

Descripción completa

Detalles Bibliográficos
Autores principales: Sottile, Rosa, Pangigadde, Pradeepa N., Tan, Thomas, Anichini, Andrea, Sabbatino, Francesco, Trecroci, Francesca, Favoino, Elvira, Orgiano, Laura, Roberts, James, Ferrone, Soldano, Kärre, Klas, Colucci, Francesco, Carbone, Ennio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Immunomodulation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832274/
https://www.ncbi.nlm.nih.gov/pubmed/26564811
http://dx.doi.org/10.1002/eji.201445289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832274/
https://www.ncbi.nlm.nih.gov/pubmed/26564811
http://dx.doi.org/10.1002/eji.201445289

Ejemplares similares